Additionally, ongoing research aims to elucidate the underlying mechanisms and molecular interactions associated with MET amplification-mediated resistance, which will inform the development of novel therapeutic strategies for patients with MET-amplified NSCLC. Here, MET is linked to non-small cell lung carcinoma.